{"url_path":"/sec/acrv/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-221626-index.html","accession_number":"0001193125-26-221626","cik":"0001781174","ticker":"ACRV","issuer_name":"Acrivon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-221626-index.html","primary_entity_key":"0001781174","primary_entity_name":"Acrivon Therapeutics, Inc."},"word_count":130,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 13, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2026, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings."}